Our present data verified that miR-320a expression was significantly decreased, while SND1 and β-catenin expressions were observably increased with the grade elevation in 120 human gliomas of WHO grade II-IV, and that the subgroups with higher miR-320a and lower SND1 and β-catenin had better prognoses in the glioma patients with the same grade, IDH status, age and KPS, suggesting that they were potential biomarkers in distinguishing glioma grades and specific biomarkers for prognostic-based glioma subclassification. The gene discussed is SND1; the disease is central nervous system cancer.